T. Rowe Price Investment Management
GILD icon

T. Rowe Price Investment Management’s Gilead Sciences GILD Stock Holding History

T. Rowe Price Investment Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32.1M Sell
230,625
-72,044
-24% -$10.1M 0.02% 411
2025
Q4 		$37.1M Buy
302,669
+35,769
+13% +$4.35M 0.02% 416
2025
Q3 		$29.6M Buy
266,900
+242,972
+1,015% +$27.6M 0.02% 460
2025
Q2 		$2.65M Buy
+23,928
New +$2.55M ﹤0.01% 594

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Investment Management's GILD Position: Q1 2026 in Review

T. Rowe Price Investment Management reduced its Gilead Sciences (GILD) stake by 24% in Q1 2026, selling an estimated $10.1M and leaving 230,625 shares worth $32.1M. The position accounts for 0.02% of the portfolio, ranked #411.

T. Rowe Price Investment Management first reported a position in GILD in Q2 2025 and has held it in 4 quarters since. The position peaked at $37.1M in Q4 2025. 2,316 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • T. Rowe Price Investment Management held 230,625 shares of Gilead Sciences worth $32.1M as of Q1 2026.
  • T. Rowe Price Investment Management sold 72,044 Gilead Sciences shares in Q1 2026, an estimated $10.1M.
  • Gilead Sciences made up 0.02% of T. Rowe Price Investment Management's portfolio in Q1 2026, its #411 holding.
  • T. Rowe Price Investment Management first reported a position in Gilead Sciences in Q2 2025 and has held it in 4 quarters since.
  • T. Rowe Price Investment Management's Gilead Sciences position peaked at $37.1M in Q4 2025.
  • 2,316 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.